Pharvaris NV
PHVS28.380USD
+0.660+2.38%
收盤 11/28, 13:00（美東）報價延遲15分鐘
1.84B總市值
虧損本益比TTM
關於 Pharvaris NV 公司
Pharvaris BV 是一家位於瑞士的臨牀階段公司。該公司的業務重點是生產口服緩激肽 B2 受體拮抗劑，並正在開發針對所有亞型遺傳性血管性水腫 (HAE) 的注射療法的新替代品。
Pharvaris NV簡介
公司代碼PHVS
公司名稱Pharvaris NV
上市日期Feb 05, 2021
CEOMr. Berndt Modig, CPA
員工數量- -
證券類型Ordinary Share
年結日Feb 05
公司地址Emmy Noetherweg 2
城市LEIDEN
上市交易所NASDAQ Global Select Consolidated
國家Netherlands
郵編2333 BK
電話31712036410
網址https://pharvaris.com/
公司代碼PHVS
上市日期Feb 05, 2021
CEOMr. Berndt Modig, CPA
Pharvaris NV公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
102.82K
-15.53%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
54.91K
+73.10%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
50.54K
+0.63%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
50.53K
+128.70%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
800.00
--
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Anne Marie De Jonge Schuermans, Ph.D.
Dr. Anne Marie De Jonge Schuermans, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Dr. Morgan Conn, Ph.D.
Dr. Morgan Conn, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
102.82K
-15.53%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
54.91K
+73.10%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
50.54K
+0.63%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
50.53K
+128.70%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
800.00
--
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
General Atlantic LLC
12.54%
Fidelity Management & Research Company LLC
9.99%
Foresite Capital Management, LLC
7.46%
VenBio Partners LLC
7.24%
Viking Global Investors LP
5.70%
其他
57.07%
持股股東
持股股東
佔比
General Atlantic LLC
12.54%
Fidelity Management & Research Company LLC
9.99%
Foresite Capital Management, LLC
7.46%
VenBio Partners LLC
7.24%
Viking Global Investors LP
5.70%
其他
57.07%
股東類型
持股股東
佔比
Private Equity
33.13%
Hedge Fund
22.83%
Investment Advisor
18.03%
Venture Capital
11.99%
Investment Advisor/Hedge Fund
9.82%
Individual Investor
5.32%
Research Firm
0.17%
Bank and Trust
0.07%
Pension Fund
0.05%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
118
49.64M
77.50%
-950.63K
2025Q2
125
52.21M
81.51%
-1.38M
2025Q1
125
53.89M
99.06%
+200.61K
2024Q4
123
53.45M
98.98%
+218.03K
2024Q3
114
53.86M
99.73%
+1.03M
2024Q2
83
52.08M
96.43%
-141.66K
2024Q1
76
49.63M
98.30%
-831.88K
2023Q4
69
47.76M
94.74%
+8.60M
2023Q3
54
36.05M
91.51%
-2.92M
2023Q2
53
35.78M
91.11%
+3.65M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
General Atlantic LLC
7.53M
11.76%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
5.42M
8.47%
+27.02K
+0.50%
Jun 30, 2025
Foresite Capital Management, LLC
4.41M
6.89%
--
--
Jun 30, 2025
VenBio Partners LLC
4.29M
6.7%
--
--
Jun 30, 2025
Viking Global Investors LP
3.65M
5.7%
--
--
Jun 30, 2025
EQT Life Sciences
3.56M
5.55%
--
--
Apr 01, 2025
Bain Capital Life Sciences Investors, LLC
3.30M
5.16%
--
--
Jun 30, 2025
Deerfield Management Company, L.P.
2.02M
3.15%
--
--
Jun 30, 2025
Commodore Capital LP
1.91M
2.98%
--
--
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
1.05%
ALPS Medical Breakthroughs ETF
0.95%
iShares MSCI Netherlands ETF
0.27%
SPDR S&P International Small Cap ETF
0.08%
iShares MSCI Europe Small-Cap ETF
0.04%
iShares MSCI EAFE Small-Cap ETF
0.02%
Fidelity Nasdaq Composite Index ETF
0.01%
Xtrackers MSCI Eurozone Hedged Eqty ETF
0.01%
Avantis International Small Cap Equity ETF
0%
First Trust IPOX Europe Equity Opportunities ETF
0%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比1.05%
ALPS Medical Breakthroughs ETF
佔比0.95%
iShares MSCI Netherlands ETF
佔比0.27%
SPDR S&P International Small Cap ETF
佔比0.08%
iShares MSCI Europe Small-Cap ETF
佔比0.04%
iShares MSCI EAFE Small-Cap ETF
佔比0.02%
Fidelity Nasdaq Composite Index ETF
佔比0.01%
Xtrackers MSCI Eurozone Hedged Eqty ETF
佔比0.01%
Avantis International Small Cap Equity ETF
佔比0%
First Trust IPOX Europe Equity Opportunities ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Pharvaris NV的前五大股東是誰？
Pharvaris NV的前五大股東如下：
General Atlantic LLC持有股份：7.53M佔總股份比例：11.76%。
Fidelity Management & Research Company LLC持有股份：5.42M佔總股份比例：8.47%。
Foresite Capital Management, LLC持有股份：4.41M佔總股份比例：6.89%。
VenBio Partners LLC持有股份：4.29M佔總股份比例：6.70%。
Viking Global Investors LP持有股份：3.65M佔總股份比例：5.70%。
General Atlantic LLC持有股份：7.53M佔總股份比例：11.76%。
Fidelity Management & Research Company LLC持有股份：5.42M佔總股份比例：8.47%。
Foresite Capital Management, LLC持有股份：4.41M佔總股份比例：6.89%。
VenBio Partners LLC持有股份：4.29M佔總股份比例：6.70%。
Viking Global Investors LP持有股份：3.65M佔總股份比例：5.70%。
Pharvaris NV的前三大股東類型是什麼？
Pharvaris NV 的前三大股東類型分別是：
General Atlantic LLC
Fidelity Management & Research Company LLC
Foresite Capital Management, LLC
General Atlantic LLC
Fidelity Management & Research Company LLC
Foresite Capital Management, LLC
有多少機構持有Pharvaris NV(PHVS)的股份？
截至2025Q3，共有118家機構持有Pharvaris NV的股份，合計持有的股份價值約為49.64M，占公司總股份的77.50% 。與2025Q2相比，機構持股有所增加，增幅為-4.01%。
哪個業務部門對Pharvaris NV的收入貢獻最大？
在--，--業務部門對Pharvaris NV的收入貢獻最大，創收--，占總收入的--% 。
